Summary | |
---|---|
Symbol | LPA |
Name | lipoprotein, Lp(a) |
Aliases | AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a) |
Chromosomal Location | 6q25-q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF00051 Kringle domain PF00089 Trypsin |
Function |
Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330. |
Biological Process |
GO:0003013 circulatory system process GO:0006869 lipid transport GO:0008015 blood circulation GO:0010466 negative regulation of peptidase activity GO:0010876 lipid localization GO:0010951 negative regulation of endopeptidase activity GO:0042157 lipoprotein metabolic process GO:0045861 negative regulation of proteolysis GO:0051346 negative regulation of hydrolase activity GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity |
Molecular Function |
GO:0001968 fibronectin binding GO:0004175 endopeptidase activity GO:0004252 serine-type endopeptidase activity GO:0004857 enzyme inhibitor activity GO:0004866 endopeptidase inhibitor activity GO:0005539 glycosaminoglycan binding GO:0008201 heparin binding GO:0008236 serine-type peptidase activity GO:0017171 serine hydrolase activity GO:0030414 peptidase inhibitor activity GO:0034185 apolipoprotein binding GO:0061134 peptidase regulator activity GO:0061135 endopeptidase regulator activity GO:1901681 sulfur compound binding |
Cellular Component |
GO:0032994 protein-lipid complex GO:0034358 plasma lipoprotein particle GO:1990777 lipoprotein particle |
KEGG | - |
Reactome |
R-HSA-171052: LDL-mediated lipid transport R-HSA-73923: Lipid digestion, mobilization, and transport R-HSA-174824: Lipoprotein metabolism R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins |
Summary | |
---|---|
Symbol | LPA |
Name | lipoprotein, Lp(a) |
Aliases | AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a) |
Chromosomal Location | 6q25-q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between LPA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | LPA |
Name | lipoprotein, Lp(a) |
Aliases | AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a) |
Chromosomal Location | 6q25-q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of LPA in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | LPA |
Name | lipoprotein, Lp(a) |
Aliases | AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a) |
Chromosomal Location | 6q25-q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of LPA in various data sets.
|
Points in the above scatter plot represent the mutation difference of LPA in various data sets.
|
Summary | |
---|---|
Symbol | LPA |
Name | lipoprotein, Lp(a) |
Aliases | AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a) |
Chromosomal Location | 6q25-q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LPA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | LPA |
Name | lipoprotein, Lp(a) |
Aliases | AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a) |
Chromosomal Location | 6q25-q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LPA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LPA. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | LPA |
Name | lipoprotein, Lp(a) |
Aliases | AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a) |
Chromosomal Location | 6q25-q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LPA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | LPA |
Name | lipoprotein, Lp(a) |
Aliases | AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a) |
Chromosomal Location | 6q25-q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of LPA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | LPA |
Name | lipoprotein, Lp(a) |
Aliases | AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a) |
Chromosomal Location | 6q25-q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between LPA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | LPA |
Name | lipoprotein, Lp(a) |
Aliases | AK38; APOA; antiangiogenic AK38 protein; apo(a); lp(a); Apolipoprotein(a) |
Chromosomal Location | 6q25-q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting LPA collected from DrugBank database. |
Details on drugs targeting LPA.
|